Institute for Clinical and Experimental Medicine — CureCurrent

How to interpret these research links

Connected source records

The exact organization name Institute for Clinical and Experimental Medicine appears in 31 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials31

Recruiting shown7

Roles2

SourceClinicalTrials.gov

Clinical trials

31 shown

Prolonged Nasogastric Administration of Ketones in Decompensated Heart FailureNCT07527156 · lead sponsor · 2026-04-04

Evaluate the Performance of the Dexcom G7 Continuous Glucose Monitoring (CGM) System in Critically Ill Patients Undergoing Major Abdominal Surgery and Solid Organ Transplantation Which Require Blood Glucose Monitoring for Intensive Insulin Therapy.NCT07611721 · lead sponsor · 2026-01-14

Mechanisms of Pulmonary Vascular Dysfunction in Heart FailureNCT06331208 · lead sponsor · 2024-08-23

Pericoronary Adipocyte Size GradientNCT07360925 · lead sponsor · 2023-06-01

Gastric Pathophysiology in DiabetesNCT06068114 · lead sponsor · 2022-10-05

Laparascopic Sleeve Gastrectomy vs. Endoscopic Gastric Plication in ObesityNCT05259644 · lead sponsor · 2022-02-01

INSULIN THERAPY DE-INTENSIFICATION WITH iGlarLixiNCT04945070 · lead sponsor · 2021-07-01

Exogenous Ketones for Acutely Decompensated HEart FailureNCT04698005 · lead sponsor · 2020-12-02

Landiolol for Rate Control in Decompensated Heart Failure Due to Atrial FibrillationNCT04694092 · lead sponsor · 2020-11-05

Compliance of Diabetic Patients Treated With MetforminNCT03864705 · lead sponsor · 2019-03-01

Anti-thrombotic Monotherapy in HeartMate 3 Left Ventricular Assist System (LVAS)NCT03781258 · lead sponsor · 2018-11-23

Anti-thrombotic Monotherapy With the HeartMate 3 LVASNCT03704220 · lead sponsor · 2018-08-16

Stimulation TcPO2 Test in the PAD Diagnosis in Diabetic FootNCT04404699 · lead sponsor · 2018-01-01

MAGENTUM 1 HeartMate 3 LVAS: A Single Center Prospective Controlled Study (MAGENTUM 1)NCT03078374 · lead sponsor · 2017-01-11

Processed Meat and Brain Regions Related to Reward and AddictionNCT02474147 · lead sponsor · 2015-08-01

The Role of Insulin Resistance in Patients With Heart Failure and Type 2 DiabetesNCT02559128 · lead sponsor · 2013-12-01

Endothelial Function in Patients With Type 2 Diabetes Versus Healthy SubjectsNCT01946347 · lead sponsor · 2013-09-01

Cardioprotective and Metabolic Effects of Metformin in Patients With Heart Failure and DiabetesNCT01690091 · lead sponsor · 2012-11-01

Postprandial Insulin Secretion, Oxidative Stress and Gastrointestinal Peptides in Patients With Type 2 Diabetes Versus Healthy SubjectsNCT01572402 · lead sponsor · 2012-01-01

Effect of Meal Frequency on Insulin Resistance in Subjects With Type 2 DiabetesNCT01277471 · lead sponsor · 2010-12-01

Does a Low-Fat Vegetarian Diet Improve Insulin Resistance in Individuals With Type 2 Diabetes?NCT00883038 · lead sponsor · 2008-07-01

Effect of Angiotensin Receptor Blockade on Insulin Resistance and Adipose Tissue Cytokines in Type 2 DiabetesNCT01011062 · lead sponsor · 2004-01-01

Sirolimus vs Mycophenolate With Tacrolimus in Simultaneous Pancreas and Kidney TransplantationNCT03582878 · lead sponsor · 2004-01-01

Polyclonal Anti-T-Lymphocyte Globulin (ATG) in Type 1 DiabetesNCT00190502 · lead sponsor · 2000-11-01

Hepatic Venous Pressure Gradient Versus Endoscopic Ultrasound-Guided Portal Pressure Gradient - Comparative Analysis (HEPCA)NCT07424963 · collaborator · 2025-05-30

Small Bowel DiversionNCT06374368 · collaborator · 2019-05-01

Can Two Dietary Interventions Maintain Weight Loss for 12 Months After GLP-1 Therapy in Adults With Overweight/Obesity?NCT07711548 · collaborator · 2027-03-01

NOT_YET_RECRUITING

Comprehensive Rehabilitation Programme in People With Multiple Sclerosis: The RECONNECT-MS StudyNCT07666958 · collaborator · 2026-07-01

NOT_YET_RECRUITING

Modification of Gut Microbiota in the Treatment of Insulin Resistance: a Personalized ApproachNCT03710850 · collaborator · 2018-05-01

Postcardiotomy Venoarterial Extracorporeal Membrane OxygenationNCT03508505 · collaborator · 2018-01-01

Efficacy of Physical Exercise in Cardiac RehabilitationNCT01617850 · collaborator · 2011-04-01

Drugs studied in this sponsor's trials

4 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Institute for Clinical and Experimental Medicine as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.

warfarin3

losartan1

mycophenolate mofetil1

placebo1

warfarin RxCUI 11289 · Lead sponsor in 3 linked trial(s) · 0 currently recruiting 3 trials losartan RxCUI 52175 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial mycophenolate mofetil RxCUI 68149 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial placebo RxCUI 8375 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial

Sponsor roles

lead sponsor24

collaborator7

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.